DIABETES TECHNOLOGY SOCIETY

EIN: 300012730 501(c)(3) Diseases & Disorders

BURLINGAME, CA

Total Revenue
$1,029,388
Total Expenses
$1,615,150
Total Assets
$1,420,913
Net Assets
$1,400,551
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
2001
Legal Domicile
CA
Principal Officer
DR DAVID C KLONOFF MD
Phone
6504919109
Tax Period
2025-01-01 to 2025-12-31

DIABETES TECHNOLOGY SOCIETY, founded in 2001, is a community nonprofit in the Diseases & Disorders sector that reported $1.0M in total revenue in fiscal year 2025. Revenue fell 47% from the prior year — a significant decline worth monitoring. Expenses of $1.6M exceeded revenue, resulting in a 57% operating deficit.

Mission

TO FACILITATE RESEARCH INTO THE TREATMENT, MONITORING, DIAGNOSIS AND PREVENTION OF DIABETES.

Program Service Accomplishments

Program 1
Expenses: $1,401,081 Revenue: $792,044

TO FURTHER EDUCATION PROFESSIONALS AND THE PUBLIC ON THE TREATMENT, MONITORING, DIAGNOSIS AND PREVENTION OF DIABETES. THIS WAS ACHIEVED BY HOLDING EDUCATIONAL CONFERENCES, MAINTAINING AN...

Read more

TO FURTHER EDUCATION PROFESSIONALS AND THE PUBLIC ON THE TREATMENT, MONITORING, DIAGNOSIS AND PREVENTION OF DIABETES. THIS WAS ACHIEVED BY HOLDING EDUCATIONAL CONFERENCES, MAINTAINING AN INFORMATIONAL WEBSITE, HOLDING AN ONGOING PODCAST WITH LEADERS IN THE DIABETES TECHNOLOGY FIELD, MAINTAINING A SPANISH/ENGLISH DUAL-LANGUAGE INFORMATIONAL WEBSITE AND PUBLISHING 204 TECHNICAL ARTICLES AND 13 RESEARCH ARTICLES ABOUT DIABETES AND DIABETES TECHNOLOGY. CONFERENCES HELD IN 2025, THE NUMBER OF ATTENDEES AND OTHER PROJECTS ARE AS FOLLOWS:1.TOOLS TO DISTINGUISH T1D & T2D IN ADULTS (TOOLS PROJECT)MEETING #1: 2/4/2025, 14 ATTENDEESMEETING #2: 2/5/2025, 14 ATTENDEESMEETING #3: 5/29/2025: 29 ATTENDEESMEETING #4: 8/13/2025, 14 ATTENDEES2. INTEGRATION OF CONNECTED DIABETES DEVICE DATA INTO THE ELECTRONIC HEALTH RECORD #2 (ICODE-2)SEPTEMBER 18, 2025NO. OF ATTENDEES: 403. THE ROLE OF THE GLYCEMIA RISK INDEX DIABETES TECHNOLOGY MEETING (GRI MEETING)OCTOBER 27, 2025NO. OF ATTENDEES: 484. DIABETES TECHNOLOGY MEETING (IN-PERSON) (DTM 2025)OCTOBER 28-30, 2025NO. OF ATTENDEES: 5005. THE USE OF CGM TO DIAGNOSE STAGE 2 T1D CONSENSUS PANEL (IN-PERSON PRESENTATION AT THE 2025 DTM)OCTOBER 30, 2025 NO. OF ATTENDEES: 500ONGOING PROJECTS:1. DIABETES RESEARCH HUB (DRH) - ONGOING PROJECTTHE DRH IS A COMPREHENSIVE DATA ECOSYSTEM DESIGNED TO ACCELERATE BREAKTHROUGHS IN DIABETES RESEARCH. WE EMPOWER RESEARCHERS BY UNLOCKING THE POTENTIAL OF DATA TRAPPED IN PROPRIETARY MEDICAL DEVICES AND HEALTH SYSTEMS. BY CREATING A SECURE AND USER-FRIENDLY PLATFORM FOR DATA COLLECTION, ANALYSIS, AND COLLABORATION, THE DRH FUELS NEXT-GENERATION RESEARCH USING AI AND ML TO DEVELOP PERSONALIZED AND EFFECTIVE SOLUTIONS FOR DIABETES.2. THE DCB OPEN INNOVATION CHALLENGEIN COLLABORATION WITH DIABETES CENTER BERNEONGOING - LAUNCHED ON 4/1/2024 & FEATURED AT THE DTM 2025 ON 10/30/20253. DIABETES TECHNOLOGY REPORT(DTS PODCAST)DTS LAUNCHED AN ONGOING PODCAST WITH LEADERS IN THE DIABETES TECHNOLOGY FIELD.4. SALUDDIABETES.ORGDTS LAUNCHED A SPANISH/ENGLISH DUAL-LANGUAGE WEBSITE THAT SUMMARIZES RECENT PUBLICATIONS IN DIABETES AND HEALTH FOR THE LAYPERSON.5. OPTIMIZING LIFESTYLE INTERVENTIONS FOR REVERSING INSULIN RESISTANCE - ONGOING PROJECTTO ANALYZE MEDICAL LITERATURE FOR INTERVENTIONS THAT IMPROVE INSULIN SENSITIVITY (EITHER BY AN EFFECT ON THE LIVER, MUSCLES, OR PRODUCTION OF INSULIN OR NATURAL GLP-1RA HORMONE) THAT COULD BECOME PART OF A BEHAVIORAL TOOL TO BE USED FOR PEOPLE WITH PREDIABETES OR WHO ARE AT RISK OF DIABETES TO DECREASE THEIR RISK OF DEVELOPING TYPE 2 DIABETES.6. JDST (JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY)PUBLISHED 204 TECHNICAL ARTICLES ABOUT DIABETES AND DIABETES TECHNOLOGY AFTER RECEIVING 628 ARTICLES TO REVIEW.7. PUBLICATION OF 13 RESEARCH ARTICLES BY DTS STAFF LISTED BELOW:-EVALUATING THE CLINICAL UTILITY OF THE GLYCEMIA RISK INDEX.J DIABETES SCI TECHNOL. 2025 OCT 14:19322968251382604. DOI: 10.1177/19322968251382604. ONLINE AHEAD OF PRINT. PMID: 41216978 FREE PMC ARTICLE.-MACHINE LEARNING TO DIAGNOSE COMPLICATIONS OF DIABETES. J DIABETES SCI TECHNOL. 2025 NOV;19(6):1650-1670. DOI: 10.1177/19322968251365245. EPUB 2025 SEP 11. PMID: 40932163 FREE PMC ARTICLE. REVIEW.-CONTINUOUS GLUCOSE MONITORING DATA ANALYSIS 2.0: FUNCTIONAL DATA PATTERN RECOGNITION AND ARTIFICIAL INTELLIGENCE APPLICATIONS. J DIABETES SCI TECHNOL. 2025 NOV;19(6):1515-1527. DOI: 10.1177/19322968251353228. EPUB 2025 AUG 14. PMID: 40814224 FREE PMC ARTICLE.-GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND PERI-PROCEDURAL ASPIRATION RISK. J ENDOCR SOC. 2025 JUL 10;9(9):BVAF088. DOI: 10.1210/JENDSO/BVAF088. ECOLLECTION 2025 SEP. PMID: 40893948 FREE PMC ARTICLE. REVIEW.-THE NEED TO TRANSITION FROM PAPER TO ELECTRONIC INSTRUCTIONS FOR USE FOR DIABETES DEVICES. NPJ DIGIT MED. 2025 JUN 13;8(1):356. DOI: 10.1038/S41746-025-01720-0. PMID: 40514391 FREE PMC ARTICLE.-DIABETES DEVICES: A GROWING ENVIRONMENTAL BURDEN. DIABETES RES CLIN PRACT. 2025 AUG;226:112307. DOI: 10.1016/J.DIABRES.2025.112307. EPUB 2025 JUN 3. PMID: 40473032 NO ABSTRACT AVAILABLE.-USE OF CONTINUOUS GLUCOSE MONITORING TO DIAGNOSE STAGE 2 TYPE 1 DIABETES. J DIABETES SCI TECHNOL. 2025 JUL;19(4):1109-1127. DOI: 10.1177/19322968251333441. EPUB 2025 MAY 30. PMID: 40444471 FREE PMC ARTICLE. REVIEW.-ENVISIONING TOOLS TO HELP CLASSIFY TYPE 1 DIABETES AND TYPE 2 DIABETES IN NEW-ONSET ADULT DIABETES. J DIABETES SCI TECHNOL. 2025 JUL;19(4):1137-1143. DOI: 10.1177/19322968251329055. EPUB 2025 MAR 28. PMID: 40152433 FREE PMC ARTICLE.-QUANTIFYING ENVIRONMENTAL WASTE FROM DIABETES DEVICES IN THE U.S. DIABETES CARE. 2025 JUL 1;48(7):1198-1203. DOI: 10.2337/DC24-2522. PMID: 40072890.-HOW TO PROVIDE ADDITIONAL OVERSIGHT TO ENSURE THAT REMOTE PATIENT MONITORING FOR PEOPLE WITH DIABETES IS BEING USED AND BILLED APPROPRIATELY. DIABETES SCI TECHNOL. 2025 MAY;19(3):843-849. DOI: 10.1177/19322968241309357. EPUB 2025 JAN 16. PMID: 39819165 FREE PMC ARTICLE.-HOW THE DIABETES RESEARCH HUB WILL MODERNIZE AND ENHANCE DIABETES DATA UTILIZATION. J DIABETES SCI TECHNOL. 2026 JAN;20(1):3-6. DOI: 10.1177/19322968241306129. EPUB 2024 DEC 21. PMID: 39707843 FREE PMC ARTICLE.-COMPARISON OF THE GLYCEMIA RISK INDEX AND TIME IN RANGE IN A CASE SERIES OF USING AUTOMATED INSULIN DELIVERY TO IMPROVE GLYCEMIC CONTROL IN PEOPLE WITH TYPE 1 DIABETES AND END STAGE KIDNEY DISEASE ON HEMODIALYSIS. DIABETES RES CLIN PRACT. 2025 JAN;219:111940. DOI: 10.1016/J.DIABRES.2024.111940. EPUB 2024 NOV 29. PMID: 39615793 NO ABSTRACT AVAILABLE.-CONSENSUS REPORT ON THE USE OF CONTINUOUS GLUCOSE MONITORING IN CHRONIC KIDNEY DISEASE AND DIABETES. J DIABETES SCI TECHNOL. 2025 JAN;19(1):217-245. DOI: 10.1177/19322968241292041. EPUB 2024 NOV 29. PMID: 39611379 FREE PMC ARTICLE.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $191,000
Program Service Revenue $792,044
Investment Income $46,344
Other Revenue $0
TOTAL REVENUE $1,029,388

Expense Breakdown

Grants Paid $4,300
Salaries & Benefits $544,655
Fundraising Expenses $0
Program Expenses $1,401,081
Other Expenses $1,066,195
TOTAL EXPENSES $1,615,150

Year-over-Year Comparison

2025 2024 Change
Revenue $1,029,388 $1,925,694 -0.5%
Expenses $1,615,150 $1,539,248 +0.0%
Net Income $-585,762 $386,446 -2.5%
Key Indicators
Grants to Organizations Grants to Individuals Lobbying Political Activity Foreign Activities Donor Advised Fund Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
4
Independent Members
3
Employees
6
Volunteers
N/A

Governance Policies

Conflict of Interest Policy
Whistleblower Policy
Document Retention Policy

Special Practices & Reported Activities

Operated a School
Operated a Hospital
Provided First Class Travel
Reported Conflict of Interest
Reported Asset Diversion
Excess Benefit Transaction
Made Political Expenditures
Engaged in Lobbying
Operated Donor Advised Fund
Maintained Art Collections
Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
1
$306,747
Total Directors
4
$306,747
Key Employees
0
$0
Highest Compensated
0
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
DR DAVID KLONOFF MD PRESIDENT 40.00
Officer Director
$297,813 $8,934 $306,747
HENRY WYKOWSKI DIRECTOR 1.00
Director
$0 $0 $0
AVERY DIAMOND DIRECTOR 1.00
Director
$0 $0 $0
DR GERALD R SYDORAK MD DIRECTOR 1.00
Director
$0 $0 $0
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2025 $1,029,388 $1,615,150 $1,420,913 $-585,762
2024 $1,925,694 $1,539,248 $2,007,874 $386,446
2023 $1,379,124 $1,103,400 $1,611,702 $275,724
2022 $1,163,946 $1,267,548 $1,334,588 $-103,602
2021 $1,063,604 $891,137 $1,434,867 $172,467
2020 $922,975 $806,021 $1,261,104 $116,954
2019 $1,183,282 $1,323,809 $1,172,416 $-140,527
2018 $1,552,220 $1,267,395 $1,328,236 $284,825
Explore More Nonprofits
Top 100 Nonprofits in California Largest U.S. Nonprofits Best Rated Nonprofits Most Efficient Nonprofits

Compare DIABETES TECHNOLOGY SOCIETY with other nonprofits in California and across the country.